Abstract:Background: Portal vein tumor thrombosis (PVTT) commonly occurs in patients with primary liver cancer (PLC). Transarterial chemoembolization (TACE) is a treatment for patients with PLC and PVTT. Some studies have shown that combining TACE therapy with hepatic arterial infusion chemotherapy (HAIC) might improve the survival rate of PLC patients with PVTT. However, few studies have compared the different regimens of PLC with PVTT. We aimed to compare the differences between the oxaliplatin + raltetrexed regimen and FOLFOX regimen. Methods: We divided the 248 patients into two groups. There were 60 patients in the oxaliplatin + ratitetrexed group and 74 patients in the FOLFOX group. The primary endpoints were OS and PFS. The secondary endpoints were ORR and adverse events. We used SPSS software, the Kaplan-Meier method, the t test, and the rank sum test to compare the differences between the two groups. Results: The median OS was 10.82 months in the oxaliplatin + raltitrexed group and 8.67 months in the FOLFOX group. The median PFS time was greater in the oxaliplatin + raltitrexed group (10.0 months) than that in the FOLFOX group (7.1 months). The ORR was greater in the oxaliplatin + raltitrexed group than that in the FOLFOX group (18.3% vs. 13.5%; P = 0.445). The DCR in the oxaliplatin + raltitrexed group was higher than that in the FOLFOX group (70.0% vs. 64.8%; P = 0.529). However, in the subgroup analysis, the difference between them was more significant in the type II PVTT subgroup. The OS was 12.08 months in the oxaliplatin + raltitrexed group and 7.26 months in the FOLFOX group (P = 0.008). The PFS was 11.68 months in the oxaliplatin + raltitrexed group and 6.26 months in the FOLFOX group (P = 0.014). In the right branch of type II PVTT, the OS was 13.54 months in the oxaliplatin + raltitrexed group and 6.89 months in the FOLFOX group (P = 0.015), and the PFS was 13.35 months in the oxaliplatin + raltitrexed group and 6.27 months in the FOLFOX group (P = 0.030). The incidence of adverse reactions was similar between the two groups. Conclusions: Compared with the FOLFOX regimen, the oxaliplatin + raltitrexed chemoembolization regimen had longer OS, PFS time and ORR and DCR and it was safe and tolerable.

Feasibility and Efficacy of Dose-reduced Transcatheter Arterial Chemoembolization (TACE) for Primary Liver Cancer Patients with Portal Vein Thrombosis

[Clinical Effect of Terminal Branches Portal Vein Embolization Combined with Transcatheter Arterial Chemoembolization on Liver Neoplasms].

Evaluation of the Curative Effect of Transcatheter Arterial Chemoembolization Via Hepatic Artery Combined with Percutaneous Ethanol Injection for the Treatment of Primary Hepatocellular Carcinoma

Therapeutic Efficacy of Transcatheter Arterial Chemoembolization for Liver Cancer with High-Risk Factors

Dose-reduced Transarterial Chemoembolization for Primary Liver Cancer Patients with Ascites

Efficacy and safety of transhepatic arterial chemoembolization with drug-loaded microspheres in unresectable primary liver cancer

Preliminary Survival Observation on Purcutaneous Portal Vein Chronomodulated Chemotherapy on Treatment of Liver Cancer.

Safety And Efficacy Of Drug-Eluting Bead Transarterial Chemoembolization With Callispheres (R) Microsphere For Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Preliminary Study

Efficacy of Licartin Combined with Transcatheter Hepatic Arterial Chemoembolization in the Treatment of Middle-Advanced Primary Liver Cancer.

Efficacy of Transarterial Chemoembolization for Hepatocellular Carcinoma with Portal Vein Thrombosis: a Meta-Analysis.

Transarterial Chemoembolization for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: a Meta-Analysis

Transcatheter arterial chemoembolization combined with endovascular 125I seed strip implantation for primary hepatocellular carcinoma associated with portal vein tumor thrombus：analysis of curative effect

Efficacy and Safety of Drug-Loaded Microsphere-Based Transcatheter Arterial Chemoembolization for the Treatment of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus

The Role of Interventional Treatment on Hepatocellular Carcinoma Combined with Portal Vein Tumor Thrombosis

Transarterial Chemoembolization Combined With Endoscopic Therapy Is Beneficial for Unresectable Hepatocellular Carcinoma With Esophagogastric Varices

Transarterial Chemoembolization in Unresectable Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis: A Tertiary Care Center Experience

The Clinical Effect in Patients with Primary Liver Cancer with Well-Filled Lipiodol after Transcatheter Arterial Chemoembolization

Safety and efficacy of transcatheter arterial chemoembolization plus early sequential percutaneous radiofrequency ablation for the treatment of large primary liver cancer with hepatitis B cirrhosis:a single-center experience

[Evaluation of the Efficacy and Prognostic Factors for Colorectal Liver Metastases Treated with Transcatheter Arterial Chemoembolization].

Sequential transcatheter arterial chemoembolization and portal vein embolization before hepatectomy for the management of patients with hepatocellular carcinoma: a systematic review and meta-analysis

Efficacy of hepatic arterial infusion chemotherapy in patients with primary liver cancer with portal vein tumor thrombosis: a comparative analysis of different perfusion chemotherapeutic regimens